Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duttaroy, A.
Right arrow Articles by Blondel, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duttaroy, A.
Right arrow Articles by Blondel, O.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:251-258, 2005
© 2005 by the American Diabetes Association, Inc.

Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology

Alokesh Duttaroy, Palanisamy Kanakaraj, Blaire L. Osborn, Helmut Schneider, Oxana K. Pickeral, Cecil Chen, Guiyi Zhang, Shashi Kaithamana, Mallika Singh, Robert Schulingkamp, Dan Crossan, Jason Bock, Thomas E. Kaufman, Peter Reavey, Melisa Carey-Barber, Surekha R. Krishnan, Andy Garcia, Kelly Murphy, Jana K. Siskind, Malia A. McLean, Susan Cheng, Steve Ruben, Charles E. Birse, and Olivier Blondel

From Human Genome Sciences, Rockville, Maryland

The primary therapeutic goal for the treatment of diabetes is maintenance of a long-term, near-normoglycemic condition and prevention of the onset or progression of the complications associated with the disease. Although several analogs of human insulin have been developed, the currently prescribed long-acting insulin analogs do not provide a stable basal glycemia for more than a few hours. Here, we report the development of Albulin, a long-acting insulin analog obtained by direct gene fusion of a single-chain human insulin to human serum albumin. Albulin showed an elimination t1/2 of ~7 h in normoglycemic mice. In vitro pharmacodynamic profiles for Albulin characterized by receptor binding, inhibition of gluconeogenesis, induction of glucose uptake, and global regulation of gene expression in relevant cell types showed that Albulin produced similar activity profiles compared with that of recombinant human insulin. A single Albulin administration in vivo normalized blood glucose level in diabetic mice in a relatively peakless and sustained (24-h) fashion. A further reduction in glucose levels was achieved by administering a recombinant human insulin a few hours after Albulin injection in mice, indicating the potential for Albulin therapy in combination with available fast-acting insulin derivatives. In summary, Albulin displays characteristics of a potent long-acting insulin analog that can be evaluated for use as a novel insulin therapy for patients with insulin-dependent diabetes.

Address correspondence and reprint requests to Olivier Blondel, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK/NIH, 6707 Democracy Blvd., Rm. 606, MSC5460, Bethesda, MD 20892-5460. E-mail: olivier.blondel{at}verizon.net


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
D. Muller, A. Karle, B. Meissburger, I. Hofig, R. Stork, and R. E. Kontermann
Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin
J. Biol. Chem., April 27, 2007; 282(17): 12650 - 12660.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.